Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx Appoints New Member to Board of Directors

NEW YORK, April 3 – Protein chip developer Zyomyx said Tuesday that Raju Kucherlapati has joined its board of directors.

Kucherlapati was a founder of Cell Genesys and Millennium Pharmaceuticals and currently serves as a director for Abgenix, Millennium, and Valentis.

Kucherlapati completed his postdoctoral work at Yale University and was awarded a PhD in genetics from the University of Illinois, Urbana.

Zyomyx of Hayward, Calif., has an agreement with Cambridge Antibody Technology to jointly develop high-density protein chips and is scheduled to begin beta testing its protein chips sometime in the first half of this year.

The privately-held company has raised $32.6 million in private financing. 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.